Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 14/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 14/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451125 | 0.91 | MEN1 (0.42) | MEN1ALDH1A1KMT2ACHRM2CHRM4 | |
| SCHEMBL6714618 | 0.82 | REN (0.47) | MEN1ALDH1A1KMT2ADRD2DRD4 | |
| SCHEMBL1450611 | 0.81 | ALDH1A1 (0.44) | MEN1ALDH1A1KMT2ACHRM2CHRM4 | |
| SCHEMBL1451152 | 0.78 | ALDH1A1 (0.52) | MEN1ALDH1A1KMT2ADRD2DRD4 | |
| SCHEMBL1451049 | 0.77 | ALDH1A1 (0.38) | MEN1ALDH1A1KMT2ADRD2DRD4 | |
| SCHEMBL6713047 | 0.76 | CYP3A4 (0.48) | MEN1ALDH1A1KMT2ACHRM2CHRM4 | |
| SCHEMBL6715255 | 0.76 | CHRM2 (0.39) | MEN1ALDH1A1KMT2ACHRM2CHRM4 | |
| SCHEMBL6716466 | 0.76 | REN (0.48) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5800838 | 0.75 | TSHR (0.47) | MEN1ALDH1A1KMT2ACHRM2CHRM4 | |
| SCHEMBL6402706 | 0.75 | ALDH1A1 (0.35) | MEN1ALDH1A1KMT2ACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | claimed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | claimed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | MEN1 4236/4885ALDH1A1 921/4885KMT2A 3763/4885 |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | MEN1 4599/4885ALDH1A1 1486/4885KMT2A 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.